April 16th 2024
Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.
Drug Price Controls: “Red Meat for the Left” or Russian Roulette?
September 18th 2015Kaiser’s August healthcare poll results should put all on high alert given public sentiment and the rhetoric of the political season. Ed Schoonveld sounds the alarm and offers four initiatives to stall the surge towards government intercession on escalating prices.
Partnering in a Volume to Value Transformational Environment
March 12th 2015In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes Cliff Kalb.